NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEO
  • CUSIP: N/A
  • Web:
  • Market Cap: $866.92 million
  • Outstanding Shares: 79,388,000
Average Prices:
  • 50 Day Moving Avg: $9.78
  • 200 Day Moving Avg: $8.56
  • 52 Week Range: $6.90 - $11.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 57.95
  • P/E Growth: 3.03
Sales & Book Value:
  • Annual Revenue: $249.02 million
  • Price / Sales: 3.51
  • Book Value: $2.13 per share
  • Price / Book: 5.17
  • EBIDTA: $26.72 million
  • Net Margins: -2.81%
  • Return on Equity: 6.09%
  • Return on Assets: 3.11%
  • Debt-to-Equity Ratio: 0.60%
  • Current Ratio: 2.37%
  • Quick Ratio: 2.21%
  • Average Volume: 340,141 shs.
  • Beta: 0.96
  • Short Ratio: 24.79

Frequently Asked Questions for NeoGenomics (NASDAQ:NEO)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, July, 25th. The company reported $0.04 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.03. The company earned $66.09 million during the quarter, compared to the consensus estimate of $62.95 million. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The company's revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.04 earnings per share. View NeoGenomics' Earnings History.

When will NeoGenomics make its next earnings announcement?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.18. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $258.23 million.

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

5 brokerages have issued twelve-month target prices for NeoGenomics' stock. Their predictions range from $9.00 to $11.00. On average, they anticipate NeoGenomics' stock price to reach $10.50 in the next twelve months. View Analyst Ratings for NeoGenomics.

What are analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:

  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (7/29/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:

  • Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
  • George A. Cardoza, Chief Financial Officer
  • Robert J. Shovlin, Chief Operating Officer
  • Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
  • Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
  • Steven A. Ross, Chief Information Officer
  • Steven G. Brodie Ph.d., Vice President - Operations
  • Jennifer Balliet, Vice President - Human Resources
  • Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
  • Maher Albitar M.D., Chief Medical Officer, Director - Research and Development

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include General Electric Co. (18.93%), Vanguard Group Inc. (3.44%), First Light Asset Management LLC (3.37%), Artisan Partners Limited Partnership (2.98%), Janus Henderson Group PLC (2.90%) and Russell Investments Group Ltd. (2.52%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Jennifer Balliet, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Uniplan Investment Counsel Inc., Wells Fargo & Company MN, Icon Advisers Inc. Co., Artisan Partners Limited Partnership, Kopp Investment Advisors LLC, Emerald Advisers Inc. PA and Swiss National Bank. Company insiders that have sold NeoGenomics stock in the last year include Jennifer Balliet, Maher Albitar, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

Who bought NeoGenomics stock? Who is buying NeoGenomics stock?

NeoGenomics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Falcon Point Capital LLC, Russell Investments Group Ltd., Granite Investment Partners LLC, Northpointe Capital LLC, Royce & Associates LP, Strs Ohio and Rice Hall James & Associates LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NeoGenomics stock can currently be purchased for approximately $11.01.

MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $10.50 (4.63% downside)

Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017BTIG ResearchDowngradeBuy -> NeutralHighView Rating Details
8/24/2017GabelliInitiated CoverageBuy$9.00HighView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond James Financial, Inc.Initiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00N/AView Rating Details
10/26/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for NeoGenomics (NASDAQ:NEO)
Earnings by Quarter for NeoGenomics (NASDAQ:NEO)
Earnings History by Quarter for NeoGenomics (NASDAQ NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$0.05N/AView Earnings Details
7/25/2017Q2 2017$0.01$0.04$62.95 million$66.09 millionViewN/AView Earnings Details
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.11 EPS
Next Year EPS Consensus Estimate: $0.19 EPS


Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 80.41%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Alison L HannahDirectorBuy20,000$9.19$183,800.00View SEC Filing  
6/22/2017Jennifer BallietVPSell10,723$8.49$91,038.27View SEC Filing  
6/5/2017Steven A RossInsiderSell70,833$7.76$549,664.08View SEC Filing  
5/26/2017Jennifer BallietVPSell3,334$7.50$25,005.00View SEC Filing  
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.00View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NeoGenomics (NASDAQ:NEO)
Latest Headlines for NeoGenomics (NASDAQ:NEO)
DateHeadline logoNeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages - September 23 at 10:48 PM logoNeoGenomics, Inc. (NEO) Upgraded at BidaskClub - September 23 at 4:10 PM logoBidaskClub Lowers NeoGenomics, Inc. (NEO) to Buy - September 17 at 3:25 PM logoNeoGenomics Reports on Impacts from Hurricane Irma - September 11 at 4:35 PM logoNeoGenomics, Inc. (NEO) Downgraded by BTIG Research to Neutral - September 11 at 8:10 AM logoNEO Crosses Above Average Analyst Target - September 9 at 6:39 AM logoBidaskClub Upgrades NeoGenomics, Inc. (NEO) to Strong-Buy - September 2 at 9:24 AM logoAnatomic Pathology Market by Product & Service, Consumables, Histopathology, Cytopathology, Application - Forecasts to 2021 - August 31 at 7:43 AM logoNeoGenomics, Inc. (NEO) Receives Consensus Recommendation of "Buy" from Analysts - August 29 at 10:48 PM logoNeoGenomics, Inc. (NEO) Earns Buy Rating from Analysts at Gabelli - August 24 at 2:48 PM logoBenzinga's Top Upgrades, Downgrades For August 24, 2017 - Benzinga - August 24 at 9:59 AM logo$65.96 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter - August 22 at 3:22 PM logoNeoGenomics, Inc. (NEO) Upgraded at ValuEngine - August 7 at 11:14 PM logoNeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Buy" by Analysts - August 5 at 12:40 AM logoFinancial Review: NeoGenomics (NEO) & RadNet (RDNT) - August 4 at 12:18 AM logo$0.03 EPS Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter - August 1 at 10:26 PM logoHead to Head Review: NeoGenomics (NASDAQ:NEO) versus RadNet (RDNT) - August 1 at 4:32 PM logoNeoGenomics, Inc. (NEO) Director Alison L. Hannah Purchases 20,000 Shares - July 31 at 7:44 PM logoNeoGenomics, Inc. (NEO) Rating Lowered to Buy at BidaskClub - July 29 at 2:19 PM logoNeoGenomics, Inc. (NEO) Upgraded at Zacks Investment Research - July 29 at 9:04 AM logoRadNet (RDNT) vs. NeoGenomics (NEO) Head to Head Contrast - July 28 at 2:31 PM logoEdited Transcript of NEO earnings conference call or presentation 25-Jul-17 2:00pm GMT - July 28 at 6:04 AM logoBRIEF-Neogenomics Inc Q2 revenue $66.1 million - July 26 at 4:00 AM logoNeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 - July 26 at 4:00 AM logoInvestor Network: NeoGenomics, Inc. to Host Earnings Call - July 26 at 4:00 AM logoNeoGenomics reports 2Q loss - July 26 at 4:00 AM logoNeoGenomics, Inc. (NEO) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - July 25 at 10:08 AM logoNeoGenomics, Inc. (NEO) Updates FY17 Earnings Guidance - July 25 at 10:08 AM logoInvestor Network Invites You to the NeoGenomics Second Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, July 25, 2017 - July 25 at 6:04 AM logoContrasting RadNet (RDNT) and NeoGenomics (NASDAQ:NEO) - July 15 at 7:46 AM logo Analysts Expect NeoGenomics, Inc. (NASDAQ:NEO) Will Announce Quarterly Sales of $63.06 Million - July 12 at 10:32 AM logoNeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages - July 11 at 12:40 AM logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.01 Per Share - July 10 at 4:26 PM logoForm 4 NEOGENOMICS INC For: Jul 05 Filed by: BRODIE STEVEN G. - July 7 at 1:46 AM logoETFs with exposure to NeoGenomics, Inc. : July 3, 2017 - July 4 at 12:23 AM logoNeoGenomics Schedules its Q2 2017 Earnings Release for July 25, 2017 - June 28 at 11:39 AM logoNeoGenomics, Inc. (NEO) Downgraded by Zacks Investment Research to "Sell" - June 27 at 7:24 AM logoJennifer Balliet Sells 10,723 Shares of NeoGenomics, Inc. (NEO) Stock - June 26 at 7:38 PM logoContrasting NeoGenomics (NEO) and Enzo Biochem (ENZ) - June 26 at 8:16 AM logoFDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies - June 24 at 5:24 AM logoNeoGenomics, Inc. (NEO) Upgraded to Hold by ValuEngine - June 24 at 12:06 AM logoETFs with exposure to NeoGenomics, Inc. : June 22, 2017 - June 23 at 8:22 AM logo$63.13 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter - June 16 at 3:30 PM logoZacks: Analysts Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.02 Per Share - June 14 at 2:04 PM logoNeoGenomics, Inc. (NEO) Receives Average Rating of "Buy" from Brokerages - June 13 at 10:51 PM logoETFs with exposure to NeoGenomics, Inc. : June 8, 2017 - June 8 at 7:41 PM logoSteven A. Ross Sells 70,833 Shares of NeoGenomics, Inc. (NEO) Stock - June 6 at 7:50 PM logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 - June 6 at 7:29 PM logoNeoGenomics, Inc. breached its 50 day moving average in a Bullish Manner : NEO-US : June 5, 2017 - June 5 at 8:59 AM logoNeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests - June 2 at 8:09 PM



NeoGenomics (NEO) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff